Pretax income is the income that a company earns before paying income taxes. Akero Therapeutics's pretax income for the
three
months ended in Dec. 2023 was $-55.19 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-151.76 Mil.
Akero Therapeutics's pretax margin was %.
Akero Therapeutics Pre-Tax Income Historical Data
The historical data trend for Akero Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Akero Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, Akero Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akero Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akero Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Akero Therapeutics's Pre-Tax Income falls into.
Akero Therapeutics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Akero Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-151.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akero Therapeutics (NAS:AKRO) Pre-Tax Income Explanation
Akero Therapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akero Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Akero Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Akero Therapeutics (Akero Therapeutics) Business Description
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AKRO has been successfully added to your 